Skip to main content

Table 5 PCR-corrected adequate clinical and parasitological response (ACPR) of artesunate-amodiaquine

From: The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

 

Survival estimates on day 28 a, b

Survival estimates on day 42 a, b

 

FDC

Co-blistered NFDC c

Loose NFDC-30

Loose NFDC-25 c

FDC

Loose NFDC-30

Age category

At risk

K-M [95% CI]

At risk

K-M [95% CI]

At risk

K-M [95% CI]

At risk

K-M [95% CI]

At risk

K-M [95% CI]

At risk

K-M [95% CI]

<1 y

207

97.8 [95.9-99.7]

77

98.7 [96.3-100]

222

93.8 [90.7-96.8]

95

90.9 [85.6-96.1]

42

95.6 [90.9-100]

28

85.7 [76.6-94.9]

1 to <5 y

2,044

97.9 [97.3-98.5]

511

96.9 [95.4-98.3]

1,340

94 [92.8-95.2]

532

92.2 [90.2-94.2]

325

95.7 [94-97.3]

103

92.5 [90-94.9]

5 to <12 y

565

98.1 [97-99.2]

192

98.6 [97-100]

317

98.8 [97.5-100]

211

97.4 [95.3-99.5]

65

95.4 [91.6-99.2]

15

98.8 [97.5-100]

≥12 y

570

98.6 [97.6-99.5]

203

99.6 [98.9-100]

140

98.6 [96.7-100]

31

100 [88.9-100.0]d

142

97.9 [96.3-99.5]

34

93.2 [86.2-100]

Region

            

West Africa

2,167

98.1 [97.6-98.7]

959

97.8 [96.9-98.7]

337

94.9 [92.6-97.2]

-

-

257

95.3 [93.3-97.3]

-

-

East Africa

299

98.9 [97.8-100]

24

100 [100-100]

921

92.8 [91.2-94.4]

869

93.4 [91.9-94.9]

81

98.9 [97.8-100]

127

89.5 [86.3-92.7]

Rest of Africa

615

98.6 [97.8-99.5]

-

-

664

98.3 [97.3-99.2]

-

-

124

97.1 [94.8-99.4]

-

-

Asia

305

95.5 [93.2-97.7]

-

-

69

93.2 [87.5-99]

-

-

112

93.8 [90.7-97]

53

90.2 [83.3-97.1]

S America

-

-

-

-

30

100 [88.7-100]d

-

-

-

-

-

-

Overall

3,386

98.1 [97.6-98.5]

983

97.9 [97-98.8]

2,021

95 [94.1-95.9]

869

93.4 [91.9-94.9]

574

96.1 [95-97.3]

180

92.1 [89.8-94.4]

  1. aKaplan-Meier estimates were generated using all the individual data rather than combining estimates from individual trials. n is the number of patients at risk (n) on day 28.
  2. bPairwise comparisons at day 28 using the Mantel-Haenszel (log-rank ) test.
  3. FDC v co-blistered NFDC (P = 0.799).
  4. FDC v loose NFDC-30 (P < 0.001).
  5. FDC v loose NFDC-25 (P < 0.001).
  6. Co-blistered NFDC v loose NFDC-30 (P < 0.001).
  7. Co-blistered NFDC v loose NFDC-25 (P < 0.001).
  8. Loose NFDC-30 v loose NFDC-25 (P = 0.036).
  9. cPatients followed up only up to 28 days.
  10. dExact confidence intervals using Wilson’s method using number of patients at risk on the given day.